Developer docs
API playgroundTry for free, no card

Search company profiles

Regenerative Patch Technologies

Full company profile

uuid000keyp

Namestring
Regenerative Patch Technologies
Legal namestring
Regenerative Patch Technologies LLC
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Regenerative Patch Technologies LLC (RPT) is a California-based, clinical-stage biotechnology company developing a stem cell-based subretinal implant, CPCB-RPE1, for the treatment of geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). The lead product is a bioengineered implant consisting of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane, intended to replace the degenerated RPE cell layer and Bruch's membrane in patients with severe vision loss. RPT has also developed a proprietary xeno-free cryopreservation technique enabling long-term storage and shipment of the implant to clinical treatment sites, addressing a major scalability constraint for cell-based therapies.

The company was founded in 2011 by Dr. Mark Humayun and Dr. David R. Hinton (USC) together with Dr. Dennis O. Clegg (UC Santa Barbara), with core technology exclusively licensed from USC, Caltech, and UC Santa Barbara. RPT completed a Phase I/IIa clinical study with a mean follow-up of 36.9 months in which 27% of treated eyes showed a >5-letter gain in visual acuity versus 7% of untreated fellow eyes, and initiated a randomized, multicenter Phase IIb PATCH AMD trial (NCT06557460) in December 2025 at sites in California, Illinois, and Texas.

RPT is pre-revenue: the implant is investigational and restricted to use within the current clinical trial, with no products on market and no licensing royalties disclosed. Operating capital has been provided by a $12.4 million CIRM grant (July 2023), the Marcus Foundation, and the University of Southern California. The go-to-market pathway is enterprise healthcare-channel: vitreo-retinal surgeons at clinical treatment sites performing outpatient subretinal implantation, with eventual commercial economics tied to per-implant pricing in the ophthalmic surgical market. Target customers are ophthalmologists, retina specialists, and the roughly 1 million US patients (8 million+ worldwide) with geographic atrophy.

Short descriptiontext

Regenerative Patch Technologies is a California-based, clinical-stage biotech developing CPCB-RPE1, a stem cell-derived retinal pigment epithelial cell implant on a synthetic parylene substrate, to restore vision in patients with geographic atrophy (advanced dry AMD). It is pre-revenue and currently running a multicenter Phase IIb trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPortola Valley, United States
HQ citystring
Portola Valley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapy, retinal implant technology, macular degeneration treatment, bioengineered cell implants, ophthalmic biotechnology
Industry2 codes
PRIMARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
Product category
Cell-Based Retinal Implants
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CPCB-RPE1 Implant (Future)
TypeOne Time License
Description

Pre-revenue clinical-stage company. The company is developing a stem cell-based implant for treatment of geographic atrophy (advanced dry AMD). Revenue will likely come from product sales upon regulatory approval. The implant is exclusively for use within current clinical trials and not available for other experimental indications or compassionate use.

regenerativepatch.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing a stem cell-based subretinal implant (CPCB-RPE1) for the treatment of geographic atrophy (advanced dry age-related macular degeneration). The implant consists of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane, replacing the damaged RPE cell layer and Bruch's membrane to restore vision.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 27% of treated eyes showed >5 letter gain in visual acuity compared to 7% of untreated fellow eyes (Phase I/IIa)
+2 more records
Product overview1 text field

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing cell-based implant technology for retinal diseases. The company operates with a single lead product: the CPCB-RPE1 implant, a bioengineered subretinal implant consisting of a polarized monolayer of human embryonic stem cell-derived RPE cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane. The implant is designed to replace damaged RPE cells and Bruch's membrane in patients with geographic atrophy (advanced dry AMD). RPT has developed a cryopreserved formulation variant of the implant that enables long-term storage and distribution to clinical sites.

Product and service2 records
1CPCB-RPE1 Implant
CategoryCell-Based Retinal Implants
Description

A bioengineered subretinal implant consisting of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane. It is intended to replace damaged RPE cells and Bruch's membrane in patients with geographic atrophy (advanced dry age-related macular degeneration) and is exclusively licensed from USC, Caltech, and UC Santa Barbara.

2Cryopreserved CPCB-RPE1 Formulation
CategoryCell-Based Retinal Implants
Description

A cryopreserved long-term storage format of the CPCB-RPE1 implant that facilitates shipment to clinical treatment sites and increases the number of geographic atrophy patients able to receive treatment. The xeno-free cryopreservation technique preserves viable and functional RPE cells in vitro and in vivo.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RPT was founded by Drs. Mark Humayun and David R. Hinton from USC. Technology to produce the CPCB-RPE1 implant is exclusively licensed from USC Stevens Center for Innovation. USC provided funding for clinical trials. Dr. Humayun is Co-Principal Investigator of The California Project to Cure Blindness.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology to produce the CPCB-RPE1 implant is exclusively licensed to RPT from Caltech.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

RPT was co-founded by Dr. Dennis O. Clegg from UCSB. Technology to produce the CPCB-RPE1 implant is exclusively licensed from UC Santa Barbara. Dr. Lincoln V. Johnson previously served as Director of the Center for the Study of Macular Degeneration and Associate Director of the Neuroscience Research Institute at UCSB. UCSB Center for Stem Cell Biology and Engineering is involved in the research.

4Retina Center of Ohio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Suber Huang, MD, MBA, FASRS and Chief Executive Officer of the Retina Center of Ohio, serves as a clinical advisor and has commented on the importance of the Phase IIb clinical trial for geographic atrophy treatment development.

regenerativepatch.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regenerative Patch Technologies

Cell-Based Retinal Implantsregenerativepatch.com

Regenerative Patch Technologies is a California-based, clinical-stage biotech developing CPCB-RPE1, a stem cell-derived retinal pigment epithelial cell implant on a synthetic parylene substrate, to restore vision in patients with geographic atrophy (advanced dry AMD). It is pre-revenue and currently running a multicenter Phase IIb trial.

What Regenerative Patch Technologies does

Regenerative Patch Technologies LLC (RPT) is a California-based, clinical-stage biotechnology company developing a stem cell-based subretinal implant, CPCB-RPE1, for the treatment of geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). The lead product is a bioengineered implant consisting of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane, intended to replace the degenerated RPE cell layer and Bruch's membrane in patients with severe vision loss. RPT has also developed a proprietary xeno-free cryopreservation technique enabling long-term storage and shipment of the implant to clinical treatment sites, addressing a major scalability constraint for cell-based therapies.

The company was founded in 2011 by Dr. Mark Humayun and Dr. David R. Hinton (USC) together with Dr. Dennis O. Clegg (UC Santa Barbara), with core technology exclusively licensed from USC, Caltech, and UC Santa Barbara. RPT completed a Phase I/IIa clinical study with a mean follow-up of 36.9 months in which 27% of treated eyes showed a >5-letter gain in visual acuity versus 7% of untreated fellow eyes, and initiated a randomized, multicenter Phase IIb PATCH AMD trial (NCT06557460) in December 2025 at sites in California, Illinois, and Texas.

RPT is pre-revenue: the implant is investigational and restricted to use within the current clinical trial, with no products on market and no licensing royalties disclosed. Operating capital has been provided by a $12.4 million CIRM grant (July 2023), the Marcus Foundation, and the University of Southern California. The go-to-market pathway is enterprise healthcare-channel: vitreo-retinal surgeons at clinical treatment sites performing outpatient subretinal implantation, with eventual commercial economics tied to per-implant pricing in the ophthalmic surgical market. Target customers are ophthalmologists, retina specialists, and the roughly 1 million US patients (8 million+ worldwide) with geographic atrophy.

Regenerative Patch Technologies firmographics

Firmographics
Name
Regenerative Patch Technologies
Legal name
Regenerative Patch Technologies LLC
Website
https://regenerativepatch.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Regenerative Patch Technologies is a California-based, clinical-stage biotech developing CPCB-RPE1, a stem cell-derived retinal pigment epithelial cell implant on a synthetic parylene substrate, to restore vision in patients with geographic atrophy (advanced dry AMD). It is pre-revenue and currently running a multicenter Phase IIb trial.
Ownership category
akta.pro rank

Regenerative Patch Technologies industry classification

Industry
Product category
Cell-Based Retinal Implants
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Stem cell therapy
  • Retinal implant technology
  • Macular degeneration treatment
  • Bioengineered cell implants
  • Ophthalmic biotechnology

Where Regenerative Patch Technologies is headquartered

Location

Headquarters

HQ city
Portola Valley
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Regenerative Patch Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. CPCB-RPE1 Implant (Future): Pre-revenue clinical-stage company. The company is developing a stem cell-based implant for treatment of geographic atrophy (advanced dry AMD). Revenue will likely come from product sales upon regulatory approval. The implant is exclusively for use within current clinical trials and not available for other experimental indications or compassionate use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Regenerative Patch Technologies product offering

Product offering

Core offering

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing a stem cell-based subretinal implant (CPCB-RPE1) for the treatment of geographic atrophy (advanced dry age-related macular degeneration). The implant consists of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane, replacing the damaged RPE cell layer and Bruch's membrane to restore vision.

Product overview

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing cell-based implant technology for retinal diseases. The company operates with a single lead product: the CPCB-RPE1 implant, a bioengineered subretinal implant consisting of a polarized monolayer of human embryonic stem cell-derived RPE cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane. The implant is designed to replace damaged RPE cells and Bruch's membrane in patients with geographic atrophy (advanced dry AMD). RPT has developed a cryopreserved formulation variant of the implant that enables long-term storage and distribution to clinical sites.

Differentiator

Problem solved

Functional benefit

Products and services

  • CPCB-RPE1 Implant A bioengineered subretinal implant consisting of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane. It is intended to replace damaged RPE cells and Bruch's membrane in patients with geographic atrophy (advanced dry age-related macular degeneration) and is exclusively licensed from USC, Caltech, and UC Santa Barbara.
  • Cryopreserved CPCB-RPE1 Formulation A cryopreserved long-term storage format of the CPCB-RPE1 implant that facilitates shipment to clinical treatment sites and increases the number of geographic atrophy patients able to receive treatment. The xeno-free cryopreservation technique preserves viable and functional RPE cells in vitro and in vivo.

Quantifiable outcome

  • 27% of treated eyes showed >5 letter gain in visual acuity compared to 7% of untreated fellow eyes (Phase I/IIa)
  • +2 more outcomes

Companies that use Regenerative Patch Technologies

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Regenerative Patch Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Regenerative Patch Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • University of Southern CaliforniacoreStrategic or Co-development PartnerRPT was founded by Drs. Mark Humayun and David R. Hinton from USC. Technology to produce the CPCB-RPE1 implant is exclusively licensed from USC Stevens Center for Innovation. USC provided funding for clinical trials. Dr. Humayun is Co-Principal Investigator of The California Project to Cure Blindness.
  • California Institute of TechnologycoreStrategic or Co-development PartnerTechnology to produce the CPCB-RPE1 implant is exclusively licensed to RPT from Caltech.
  • University of California, Santa BarbaracoreStrategic or Co-development PartnerRPT was co-founded by Dr. Dennis O. Clegg from UCSB. Technology to produce the CPCB-RPE1 implant is exclusively licensed from UC Santa Barbara. Dr. Lincoln V. Johnson previously served as Director of the Center for the Study of Macular Degeneration and Associate Director of the Neuroscience Research Institute at UCSB. UCSB Center for Stem Cell Biology and Engineering is involved in the research.
  • Retina Center of OhiominorStrategic or Co-development PartnerDr. Suber Huang, MD, MBA, FASRS and Chief Executive Officer of the Retina Center of Ohio, serves as a clinical advisor and has commented on the importance of the Phase IIb clinical trial for geographic atrophy treatment development.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Regenerative Patch Technologies competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Regenerative Patch Technologies social profiles

Digital presence

Regenerative Patch Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regenerative Patch Technologies leadership team

Management profile

Number of profiles

Profiles7 records

Regenerative Patch Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regenerative Patch Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenerative Patch Technologies

What does Regenerative Patch Technologies do?

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing a stem cell-based subretinal implant (CPCB-RPE1) for the treatment of geographic atrophy (advanced dry age-related macular degeneration). The implant consists of a polarized monolayer of human embryonic stem cell-derived retinal pigmented epithelial (hESC-RPE) cells on an ultrathin synthetic parylene substrate designed to mimic Bruch's membrane, replacing the damaged RPE cell layer and Bruch's membrane to restore vision.

Is Regenerative Patch Technologies a public or private company?

Regenerative Patch Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Regenerative Patch Technologies founded?

Regenerative Patch Technologies was founded in 2010. It employs 1 to 10 people.

Where is Regenerative Patch Technologies based?

Regenerative Patch Technologies is headquartered in Portola Valley, United States, in the North America region.

How does Regenerative Patch Technologies make money?

One revenue line is on record: CPCB-RPE1 Implant (Future).

Does Regenerative Patch Technologies have an API?

No public API is recorded for Regenerative Patch Technologies.

What industry is Regenerative Patch Technologies in?

Regenerative Patch Technologies's product category is Cell-Based Retinal Implants. Its primary akta.pro industry code is HLAAAGAK, Ophthalmic Regeneration (cornea/retina), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesAngiogenesis, Exudation and Degeneration 2022: Spotlighting major advances in retinal diagnostics and therapiesThe Angiogenesis, Exudation, and Degeneration 2022 virtual conference, sponsored by the Bascom Palmer Eye Institute, took place on February 11 and 12 in Miami, Florida, focusing on advancements in retinal diagnostics and therapies. Key discussions included innovative technologies for early detection of age-related macular degeneration (AMD) and novel treatments, such as Xiflam from InflammX Therapeutics and the CPCB-RPE1 implant from Regenerative Patch Technologies. Researchers also highlighted the approval of significant new therapies including faricimab and the Port Delivery System for AMD treatment.SciTechDailyCould a Tiny Eye Implant Reverse Macular Degeneration?Keck Medicine of USC has initiated a phase 2b clinical trial to test a stem cell-derived retinal implant for reversing vision loss in patients with advanced dry age-related macular degeneration. The implant, manufactured by Regenerative Patch Technologies LLC, utilizes lab-grown retinal pigment epithelium cells designed to replace damaged tissue and restore sight. Early research indicated the treatment is safe and well-tolerated, prompting this larger study to evaluate clinically significant vision improvements.PR NewswireRegenerative Patch Technologies (RPT) Announces Treatment of First Two Patients in Phase IIb Clinical Trial Assessing the Safety and Efficacy of its Allogeneic Bioengineered RPE Cell Implant for the TRegenerative Patch Technologies LLC (RPT) announced the treatment of the first two participants in its Phase IIb clinical trial for the CPCB-RPE1 implant targeting advanced dry age-related macular degeneration. The trial aims to confirm safety and efficacy signals observed in the earlier Phase I/IIa trial, which showed promising results in improving vision. This trial marks a significant step in developing therapies that may improve vision for patients suffering from geographic atrophy.Usc$6 million grant drives potential treatment for common cause of vision loss toward the clinicThe California Institute for Regenerative Medicine (CIRM) awarded a $6 million grant to researchers at USC to develop a new injection treatment for dry age-related macular degeneration. This therapy utilizes secretions from stem cell-derived retinal pigment epithelium cells, aiming to halt or reverse vision loss in the early stages of the disease. The project builds on previous CIRM-supported work commercialized by Regenerative Patch Technologies and includes preliminary discussions with the FDA.News-MedicalStem cell patch for treating macular degeneration to enter phase 2b clinical trialA stem cell patch for macular degeneration will enter a phase 2b clinical trial, with CIRM awarding $12.4 million to Regenerative Patch Technologies. The trial will test the implant in 24 patients with geographic atrophy, a condition affecting over 1 million Americans. The patch aims to restore retinal structure and function.LegacyDavid Hinton Obituary (2022)David Hinton, a prominent pathology professor and researcher at the University of Southern California Keck School of Medicine, died on June 7, 2022. He was a founding member of Regenerative Patch Technologies, a startup he established to conduct clinical trials for stem cell-based treatments for Age-Related Macular Degeneration. His career included nearly 400 publications and significant leadership roles in medical education and research administration.